News
Almathera selects IBA to equip Kazakhstan’s first private radiopharmacy and theranostics complex with Cyclone® KIUBE 300
Almathera selects IBA to equip Kazakhstan’s first private radiopharmacy and theranostics complex with Cyclone® KIUBE 300
See more
Rigging of the Cyclone® IKON at CNRT in China
Successful rigging of the 2ⁿᵈ worldwide IBA high-energy cyclotron, Cyclone® IKON, in Chengdu, Sichuan, China
See moreIBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US
IBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US
See moreIBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the first quarter ending 31 March 2024.
See moreIBA Reports Half Year 2024 Results
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the first quarter ending 31 March 2024.
See more
Rigging of the Cyclone® KIUBE at AMS Pharmaceutical in China
Rigging of the Cyclone® KIUBE at AMS Pharmaceutical in China
See moreIBA Business Update – First Quarter 2024
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the first quarter ending 31 March 2024.
See more
IBA Radio Pharma Solutions delegation in Japan
In March, a delegation of IBA Radio Pharma Solutions took the opportunity to be in Japan to visit our customers JFE Engineering Corporation, Sceti K.K., CMI and PDRadiopharma Inc.
See moreIBA Reports Full Year 2023 Results
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year. [...]
See more